They also developed the EGFR-targeting ET peptide and improved the delivery of paclitaxel to EGFR-positive lung cancer cells and thus improved the treatment outcomes in a mouse model of EGFR-positive lung cancer. This evidence concerns the gene EGFR and lung cancer.